| Species |
Human |
| Protein Construction |
NRG-1β2 (Ser177-Gln237)
Accession # Q02297-7 |
|
| Purity |
> 96% as analyzed by SDS-PAGE
> 96% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using serum free human MCF-7 cells is less than 50.0 ng/ml, corresponding to a specific activity of > 2.0 × 104 IU/mg. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
7.0 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.0, containing 0.5 % HAS and 2 % mannitol. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -20°C or -70°C. Upon reconstitution, the product should be stable for up to 1 week at 2-8°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Neuregulin is a signaling protein for ErbB2/ErbB4 receptor heterodimers on the cardiac muscle cells, playing an important role in heart structure and function through inducing ErbB2/ErbB4 receptor phosphorylation and cardiomyocyte differentiation. Research on molecular level discovered that recombinant neuregulin could make disturbed myocardial cell structure into order and strengthen the connection between myocardial cells by intercalated discs re-organization. |
| Synonyms |
NRG-1 EGF-like domain beta 2; Beta2; Neuregulin-1 beta 2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
